Company profile for Boehringer Ingelheim GmbH

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The Boehringer Ingelheim group of companies objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate culture. Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim....
The Boehringer Ingelheim group of companies objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate culture. Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Corporate Division Communications, Binger Strasse 173, 55216 Ingelheim am Rhei...
Telephone
Telephone
+49 - 6132 - 77 0
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
“Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”
This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

Impressions: 4658

https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

Radio Compass
16 Dec 2024

VLOG #PharmaReel

[Sponsored by another company]

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions
The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 

Impressions: 580

https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

#PharmaFlow by PHARMACOMPASS
19 Dec 2024

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercepharma.com/marketing/boehringer-lilly-bring-it-takes-2-kidney-disease-testing-push-2025-rose-bowl-parade

FIERCE PHARMA
11 Dec 2024

https://www.prnewswire.com/news-releases/core-kidney-boehringer-ingelheim-and-lilly-are-turning-up-the-volume-on-kidney-health-at-the-2025-tournament-of-roses-parade-302325335.html

PR NEWSWIRE
09 Dec 2024

https://www.indianpharmapost.com/news/torrent-pharma-inks-agreement-with-boehringer-ingelheim-to-acquire-3-anti-diabetes-brands-16499

INDPHARMAPOST
05 Dec 2024

https://www.pharmabiz.com/NewsDetails.aspx?aid=173845&sid=2

PHARMABIZ
30 Nov 2024

https://www.reuters.com/legal/government/latest-zantac-trial-against-boehringer-ingelheim-ends-with-hung-jury-2024-11-22/

REUTERS
21 Nov 2024

https://www.globenewswire.com/news-release/2024/11/19/2983595/0/en/Boehringer-s-focus-on-Health-Equity-drives-significant-upgrade-in-Access-to-Medicine-Index-Ranking.html

GLOBENEWSWIRE
19 Nov 2024

01

Epinastine Hydrochloride

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Epinastine Hydrochloride

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS arrow-down JDMF arrow-down EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

02

Ipratropium Bromide

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Ipratropium Bromide

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF arrow-down EU-WC NDC arrow-down KDMF arrow-down VMF Others AUDIT
blank

03

Repaglinide

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Repaglinide

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF arrow-down EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

04

Ambroxol Hydrochloride

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Ambroxol Hydrochloride

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF CEP/COS arrow-down JDMF arrow-down EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

05

Digoxin

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Digoxin

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF Inactive-api CEP/COS Inactive-api JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank

06

Epinephrine

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Epinephrine

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF Inactive-api CEP/COS Inactive-api JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank

07

Ketoprofen

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Ketoprofen

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF Inactive-api CEP/COS Inactive-api JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank

08

Pramipexole Dihydrochloride

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Pramipexole Dihydrochloride

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

09

Salbutamol Sulphate

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Salbutamol Sulphate

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Scopolamine Hydrobromide

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Scopolamine Hydrobromide

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF Inactive-api CEP/COS Inactive-api JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

03

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

04

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

05

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

06

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

08

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

09

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

10

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

read-more
read-more

01

Adrenaline

CEP/COS

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

02

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

03

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

04

Atropine

CEP/COS

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

05

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

06

Bisacodyl

CEP/COS

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

07

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

08

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

09

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

10

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-more

01

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

Registration Number : 220MF10085

Registrant's Address : S. S. 11 Padana Superiore,N. 8 24040 Fornovo San Giovanni

Initial Date of Registration : 2008-03-18

Latest Date of Registration : 2008-03-18

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

Registration Number : 219MF10046

Registrant's Address : S. S. 11 Padana Superiore,N. 8 24040 Fornovo San Giovanni

Initial Date of Registration : 2007-02-13

Latest Date of Registration : 2007-02-13

blank

03

Digoxin

JDMF

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registration Number : 218MF10484

Registrant's Address : Binger Strasse 173,55216 Ingelheim am Rhein Germany

Initial Date of Registration : 2006-05-15

Latest Date of Registration : 2015-12-15

blank

04

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registration Number : 224MF10100

Registrant's Address : Binger Strasse 173,55216 Ingelheim am Rhein

Initial Date of Registration : 2012-05-23

Latest Date of Registration : 2017-10-06

blank

05

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registration Number : 218MF10483

Registrant's Address : Binger Strasse 173, 55216 Ingelheim am Rhein Germany

Initial Date of Registration : 2006-05-15

Latest Date of Registration : 2015-12-15

blank

06

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registration Number : 218MF10495

Registrant's Address : 2820 North Normandy Drive Petersburg, Virginia 23805

Initial Date of Registration : 2006-05-15

Latest Date of Registration : 2010-03-25

blank

07

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registration Number : 220MF10081

Registrant's Address : Binger Strasse 173,55216 Ingelheim am Rhein

Initial Date of Registration : 2008-03-14

Latest Date of Registration : 2023-11-08

blank

08

Ketoprofen

JDMF

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

Registration Number : 218MF10395

Registrant's Address : S. S. 11 Padana Superior N. 8 24040 Fornovo S. Giovanni BG Italy

Initial Date of Registration : 2006-03-20

Latest Date of Registration : 2006-08-23

blank

09

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

Registration Number : 220MF10132

Registrant's Address : S. S. 11 Padana Superiore,N. 8 24040 Fornovo San Giovanni

Initial Date of Registration : 2008-05-20

Latest Date of Registration : 2015-05-01

blank

10

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registration Number : 221MF10144

Registrant's Address : Binger Strasse 173,55216 Ingelheim am Rhein

Initial Date of Registration : 2009-07-09

Latest Date of Registration : 2017-05-16

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-more

01

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

Registrant Name : Opella Healthcare Korea Co., Ltd.

Registration Date : 2005-08-31

Registration Number : 20050831-45-B-117-04

Manufacturer Name : Bidachem SpA

Manufacturer Address : SS 11(Padana Superiore), 8 24040 Fornovo San Giovanni

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

Registrant Name : Boehringer Ingelheim Korea Ltd.

Registration Date : 2010-10-11

Registration Number : Su426-2-ND

Manufacturer Name : Bidachem SpA

Manufacturer Address : Strada Statale 11 (Padana Superiore), N.8 24040 Fornovo San Giovanni (BG) ITALY

blank

03

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registrant Name : Boehringer Ingelheim Korea Ltd.

Registration Date : 2010-10-11

Registration Number : Su426-1-ND

Manufacturer Name : Boehringer Ingelheim Pharma Gm...

Manufacturer Address : Binger Strasse 173, 55216 Ingelheim am Rhein

blank

04

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

Registrant Name : Boehringer Ingelheim Korea Ltd.

Registration Date : 2018-01-15

Registration Number : 15-8-ND

Manufacturer Name : (Except for micronization proc...

Manufacturer Address : Strada Statale 11 (Padana Superiore), N. 8, 24040 Fornovo San Giovanni (BG), ITALY@Bi...

blank

05

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registrant Name : Boehringer Ingelheim Korea Ltd.

Registration Date : 2014-05-21

Registration Number : No. 2807-5-ND

Manufacturer Name : Boehringer Ingelheim Pharma Gm...

Manufacturer Address : Binger Straβe 173, D-55216 Ingelheim, Germany

blank

06

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registrant Name : Boehringer Ingelheim Korea Ltd.

Registration Date : 2013-01-09

Registration Number : 20130109-194-I-63-01

Manufacturer Name : Boehringer Ingelheim GmbH & Co...

Manufacturer Address : Binger Strasse 173 55216 Ingelheim am Rhein, Germany

blank

07

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registrant Name : Boehringer Ingelheim Korea Ltd.

Registration Date : 2012-09-19

Registration Number : 20120919-188-I-64-01

Manufacturer Name : Boehringer Ingelheim Pharma Gm...

Manufacturer Address : Binger Strasse 173, 55216 Ingelheim am Rhein

blank

08

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

Registrant Name : Boehringer Ingelheim Korea Ltd.

Registration Date : 2012-11-14

Registration Number : 20121114-148-I-85-06

Manufacturer Name : Bidachem SpA

Manufacturer Address : Strada Statale 11(Padana Superiore), N. 8, 24040 Fornovo San Giovanni (BG), Italy

blank

09

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registrant Name : Boehringer Ingelheim Korea Ltd.

Registration Date : 2015-07-13

Registration Number : No. 2807-7-ND

Manufacturer Name : Boehringer Ingelheim Pharma Gm...

Manufacturer Address : Binger Straße 173, D-55216 Ingelheim, Germany

blank

10

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Registrant Name : Heilion Korea Co., Ltd.

Registration Date : 2008-06-27

Registration Number : 20080627-88-D-82-06

Manufacturer Name : Boehringer Ingelheim Pharma Gm...

Manufacturer Address : 55216 Ingelheim Binger Str.173

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

NDC Package Code : 12714-213

Start Marketing Date : 2015-01-06

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1.1mg/1.1mg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

NDC Package Code : 12714-083

Start Marketing Date : 1987-11-13

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (100mg/100mg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

03

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

NDC Package Code : 12714-082

Start Marketing Date : 1987-11-13

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (50mg/50mg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

04

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

NDC Package Code : 12714-034

Start Marketing Date : 2004-09-17

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

NDC Package Code : 12714-031

Start Marketing Date : 2001-07-09

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

NDC Package Code : 51869-0009

Start Marketing Date : 2016-04-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1000g/1000g)

Marketing Category : EXPORT ONLY

blank

07

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

NDC Package Code : 12714-011

Start Marketing Date : 2019-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

NDC Package Code : 51869-0030

Start Marketing Date : 2011-08-08

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (20kg/20kg)

Marketing Category : BULK INGREDIENT

blank

09

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Bidachem

NDC Package Code : 51869-0015

Start Marketing Date : 2016-02-18

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (20kg/20kg)

Marketing Category : BULK INGREDIENT

blank

10

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

NDC Package Code : 12714-201

Start Marketing Date : 2016-02-18

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
click full view

VMF

read-more
read-more

09

ML-3,314,163

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

BI 1820237 is a potent, specific peptidic NPY2R agonist in development for the treatment of overweight/obesity via once-weekly subcutaneous injection


Lead Product(s): BI 1820237,BI 456906

Therapeutic Area: Nutrition and Weight Loss Brand Name: BI 1820237

Study Phase: Phase IProduct Type: Peptide

Recipient: Gubra

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 31, 2024

blank

01

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : BI 1820237 is a potent, specific peptidic NPY2R agonist in development for the treatment of overweight/obesity via once-weekly subcutaneous injection

Brand Name : BI 1820237

Molecule Type : Peptide

Upfront Cash : Not Applicable

October 31, 2024

blank

Details:

The collaboration aims to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers.


Lead Product(s): Macrocycle-based Therapy

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: PreclinicalProduct Type: Small molecule

Recipient: Circle Pharma

Deal Size: $607.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration October 09, 2024

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : The collaboration aims to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Undisclosed

October 09, 2024

blank

Details:

BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).


Lead Product(s): Survodutide

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: BI 456906

Study Phase: Phase IIIProduct Type: Peptide

Recipient: Zealand Pharma

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 07, 2024

blank

03

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Brand Name : BI 456906

Molecule Type : Peptide

Upfront Cash : Not Applicable

October 07, 2024

blank

Details:

Surrozen collaborates with Boehringer to research & develop SZN-413 to treat retinal diseases and will receive an exclusive, worldwide license to develop other Fzd4-specific Wnt-modulating molecules.


Lead Product(s): SZN-413

Therapeutic Area: Ophthalmology Brand Name: SZN-413

Study Phase: PreclinicalProduct Type: Large molecule

Recipient: Surrozen

Deal Size: $599.0 million Upfront Cash: $12.5 million

Deal Type: Collaboration September 24, 2024

blank

04

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Surrozen collaborates with Boehringer to research & develop SZN-413 to treat retinal diseases and will receive an exclusive, worldwide license to develop other Fzd4-specific Wnt-modulating molecules.

Brand Name : SZN-413

Molecule Type : Large molecule

Upfront Cash : $12.5 million

September 24, 2024

blank

Details:

BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis.


Lead Product(s): Nerandomilast

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BI 1015550

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 16, 2024

blank

05

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis.

Brand Name : BI 1015550

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 16, 2024

blank

Details:

BI 1810631 (zongertinib) is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations.


Lead Product(s): Zongertinib

Therapeutic Area: Oncology Brand Name: BI 1810631

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 09, 2024

blank

06

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : BI 1810631 (zongertinib) is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations.

Brand Name : BI 1810631

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 09, 2024

blank

Details:

BI 771716, developed with technology licensed from CDR-Life, is a highly specific antibody fragment of reduced size, enabling an optimized penetration in patients with GA disease pathology.


Lead Product(s): BI 771716

Therapeutic Area: Ophthalmology Brand Name: BI 771716

Study Phase: Phase IProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 05, 2024

blank

07

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Lead Product(s) : BI 771716

Therapeutic Area : Ophthalmology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : BI 771716, developed with technology licensed from CDR-Life, is a highly specific antibody fragment of reduced size, enabling an optimized penetration in patients with GA disease pathology.

Brand Name : BI 771716

Molecule Type : Large molecule

Upfront Cash : Not Applicable

September 05, 2024

blank

Details:

Through the acquisition, Boehringer will leverage the Nerio oncology Pipeline, which consists of small molecules that inhibit the PTPN1/2, enhance immune function, and sensitize tumors.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Small molecule

Recipient: Nerio Therapeutics

Deal Size: $1,300.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition July 29, 2024

blank

08

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Through the acquisition, Boehringer will leverage the Nerio oncology Pipeline, which consists of small molecules that inhibit the PTPN1/2, enhance immune function, and sensitize tumors.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Undisclosed

July 29, 2024

blank

Details:

Spevigo (spesolimab) is an IL-36 blocker, given by IV infusion, has been approved by CDSCO as the first treatment option for generalized pustular psoriasis flares in adults.


Lead Product(s): Spesolimab

Therapeutic Area: Dermatology Brand Name: Spevigo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 29, 2024

blank

09

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Lead Product(s) : Spesolimab

Therapeutic Area : Dermatology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Spevigo (spesolimab) is an IL-36 blocker, given by IV infusion, has been approved by CDSCO as the first treatment option for generalized pustular psoriasis flares in adults.

Brand Name : Spevigo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

July 29, 2024

blank

Details:

NBL-001 (volasertib) is a PLK-1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of relapsed/refractory acute myeloid leukemia.


Lead Product(s): Volasertib

Therapeutic Area: Oncology Brand Name: NBL-001

Study Phase: Phase IProduct Type: Small molecule

Recipient: Notable Labs

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 24, 2024

blank

10

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : NBL-001 (volasertib) is a PLK-1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of relapsed/refractory acute myeloid leukemia.

Brand Name : NBL-001

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 24, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Brand Name : ATRAVET 10 MG INJECT...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ATRAVET 10 MG INJECT...

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Dosage Form : SOLUTION

Brand Name : ATRAVET 10 MG INJECTABLE

Dosage Strength : 10MG/ML

Packaging : 50 ML

Approval Date :

Application Number : 53023

Regulatory Info : OTC

Registration Country : Canada

blank

02

Brand Name : Zerinetta C.M.

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : Zerinetta C.M.

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Dosage Form :

Brand Name : Zerinetta C.M.

Dosage Strength : 10 Supp 150 Mg + 1 Mg ...

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

03

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

ROXANE

Dosage Form : TABLET;ORAL

Brand Name : ACETAMINOPHEN AND CODEINE...

Dosage Strength : 500MG;15MG

Packaging :

Approval Date : 1989-04-25

Application Number : 89511

Regulatory Info : DISCN

Registration Country : USA

blank

04

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

ROXANE

Dosage Form : TABLET;ORAL

Brand Name : ACETAMINOPHEN AND CODEINE...

Dosage Strength : 500MG;60MG

Packaging :

Approval Date : 1989-04-25

Application Number : 89513

Regulatory Info : DISCN

Registration Country : USA

blank

05

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

ROXANE

Dosage Form : TABLET;ORAL

Brand Name : ACETAMINOPHEN AND CODEINE...

Dosage Strength : 300MG;15MG

Packaging :

Approval Date : 1982-01-01

Application Number : 84659

Regulatory Info : DISCN

Registration Country : USA

blank

06

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

ROXANE

Dosage Form : TABLET;ORAL

Brand Name : ACETAMINOPHEN AND CODEINE...

Dosage Strength : 500MG;30MG

Packaging :

Approval Date : 1989-04-25

Application Number : 89512

Regulatory Info : DISCN

Registration Country : USA

blank

07

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

ROXANE

Dosage Form : TABLET;ORAL

Brand Name : ACETAMINOPHEN AND CODEINE...

Dosage Strength : 300MG;30MG

Packaging :

Approval Date : 1982-01-01

Application Number : 84656

Regulatory Info : DISCN

Registration Country : USA

blank

08

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

ROXANE

Dosage Form : TABLET;ORAL

Brand Name : ACETAMINOPHEN AND CODEINE...

Dosage Strength : 300MG;60MG

Packaging :

Approval Date : 1982-01-01

Application Number : 84667

Regulatory Info : DISCN

Registration Country : USA

blank

09

Brand Name : ROXILOX

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ROXILOX

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

ROXANE

Dosage Form : CAPSULE;ORAL

Brand Name : ROXILOX

Dosage Strength : 500MG;5MG

Packaging :

Approval Date : 1995-07-03

Application Number : 40061

Regulatory Info : DISCN

Registration Country : USA

blank

10

Brand Name : ROXICET 5/500

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ROXICET 5/500

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

ROXANE

Dosage Form : TABLET;ORAL

Brand Name : ROXICET 5/500

Dosage Strength : 500MG;5MG

Packaging :

Approval Date : 1989-01-12

Application Number : 89775

Regulatory Info : DISCN

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ROXANE

Dosage Form : TABLET; ORAL

Proprietary Name : ACETAMINOPHEN AND CODEIN...

Dosage Strength : 300MG;30MG

Approval Date : 1982-01-01

Application Number : 84656

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

02

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ROXANE

Dosage Form : TABLET; ORAL

Proprietary Name : ACETAMINOPHEN AND CODEIN...

Dosage Strength : 300MG;15MG

Approval Date : 1982-01-01

Application Number : 84659

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

03

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ROXANE

Dosage Form : TABLET; ORAL

Proprietary Name : ACETAMINOPHEN AND CODEIN...

Dosage Strength : 300MG;60MG

Approval Date : 1982-01-01

Application Number : 84667

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

04

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ROXANE

Dosage Form : TABLET; ORAL

Proprietary Name : ACETAMINOPHEN AND CODEIN...

Dosage Strength : 500MG;15MG

Approval Date : 1989-04-25

Application Number : 89511

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

05

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ROXANE

Dosage Form : TABLET; ORAL

Proprietary Name : ACETAMINOPHEN AND CODEIN...

Dosage Strength : 500MG;30MG

Approval Date : 1989-04-25

Application Number : 89512

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

06

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETAMINOPHEN AND CO...

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ROXANE

Dosage Form : TABLET; ORAL

Proprietary Name : ACETAMINOPHEN AND CODEIN...

Dosage Strength : 500MG;60MG

Approval Date : 1989-04-25

Application Number : 89513

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

07

Brand Name : ROXILOX

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ROXILOX

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ROXANE

Dosage Form : CAPSULE; ORAL

Proprietary Name : ROXILOX

Dosage Strength : 500MG;5MG

Approval Date : 1995-07-03

Application Number : 40061

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

08

Brand Name : ROXICET 5/500

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ROXICET 5/500

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ROXANE

Dosage Form : TABLET; ORAL

Proprietary Name : ROXICET 5/500

Dosage Strength : 500MG;5MG

Approval Date : 1989-01-12

Application Number : 89775

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

09

Brand Name : ACETYLCYSTEINE

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETYLCYSTEINE

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ROXANE

Dosage Form : SOLUTION; INHALATION, ORAL

Proprietary Name : ACETYLCYSTEINE

Dosage Strength : 10%

Approval Date : 1992-04-30

Application Number : 72323

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

10

Brand Name : ACETYLCYSTEINE

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : ACETYLCYSTEINE

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ROXANE

Dosage Form : SOLUTION; INHALATION, ORAL

Proprietary Name : ACETYLCYSTEINE

Dosage Strength : 10%

Approval Date : 1992-09-30

Application Number : 72621

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank
click full view

Listed Dossiers

read-more
read-more

01

Brand Name : N/A

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Brand Name : N/A

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Boehringer Ingelheim GmbH

Dosage Form : Injection

Brand Name :

Dosage Strength : 1.8G

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Germany

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact BOEHRINGER INGELHEIM and get a quotation

BOEHRINGER INGELHEIM is a supplier offers 86 products (APIs, Excipients or Intermediates).

Find a price of Epinastine Hydrochloride bulk with DMF, CEP, JDMF offered by BOEHRINGER INGELHEIM

Find a price of Ipratropium Bromide bulk with DMF, CEP, JDMF offered by BOEHRINGER INGELHEIM

Find a price of Repaglinide bulk with DMF, CEP, JDMF offered by BOEHRINGER INGELHEIM

Find a price of Digoxin bulk with JDMF offered by BOEHRINGER INGELHEIM

Find a price of Epinephrine bulk with JDMF offered by BOEHRINGER INGELHEIM

Find a price of Pramipexole Dihydrochloride bulk with DMF, CEP offered by BOEHRINGER INGELHEIM

Find a price of Salbutamol Sulphate bulk with DMF, CEP offered by BOEHRINGER INGELHEIM

Find a price of Scopolamine Hydrobromide bulk with JDMF offered by BOEHRINGER INGELHEIM

Find a price of Dipyridamole bulk with DMF offered by BOEHRINGER INGELHEIM

Find a price of Doxapram Hydrochloride bulk with JDMF offered by BOEHRINGER INGELHEIM

Find a price of Hyoscine Butyl Bromide bulk with CEP offered by BOEHRINGER INGELHEIM

Find a price of Tiotropium Bromide bulk with CEP offered by BOEHRINGER INGELHEIM

Find a price of Atropine bulk offered by BOEHRINGER INGELHEIM

Find a price of Atropine Sulfate bulk offered by BOEHRINGER INGELHEIM

Find a price of Brotizolam bulk with CEP offered by BOEHRINGER INGELHEIM

Find a price of Clenbuterol Hydrochloride bulk with CEP offered by BOEHRINGER INGELHEIM

Find a price of Clonidine bulk with CEP offered by BOEHRINGER INGELHEIM

Find a price of Dihydroergotamine Mesylate bulk offered by BOEHRINGER INGELHEIM

Find a price of Epinephrine Bitartrate bulk offered by BOEHRINGER INGELHEIM

Find a price of Ergotamine Tartrate bulk offered by BOEHRINGER INGELHEIM

Find a price of Etilefrine bulk with CEP offered by BOEHRINGER INGELHEIM

Find a price of Fenoterol Hydrobromide bulk with CEP offered by BOEHRINGER INGELHEIM

Find a price of Homatropine Hydrobromide bulk offered by BOEHRINGER INGELHEIM

Find a price of Homatropine Methylbromide bulk offered by BOEHRINGER INGELHEIM

Find a price of Hyoscyamine Sulfate bulk offered by BOEHRINGER INGELHEIM

Find a price of Methocarbamol bulk with DMF offered by BOEHRINGER INGELHEIM

Find a price of Methylphenidate Hydrochloride bulk offered by BOEHRINGER INGELHEIM

Find a price of Moxonidine bulk offered by BOEHRINGER INGELHEIM

Find a price of Phenylephrine Hydrochloride bulk offered by BOEHRINGER INGELHEIM

Find a price of Pramipexole Dihydrochloride bulk with CEP offered by BOEHRINGER INGELHEIM

Find a price of Scopolamine bulk offered by BOEHRINGER INGELHEIM

Find a price of Tramazoline Hydrochloride Monohydrate bulk with CEP offered by BOEHRINGER INGELHEIM

Find a price of Trospium Chloride bulk offered by BOEHRINGER INGELHEIM

Find a price of Zolpidem Tartrate bulk offered by BOEHRINGER INGELHEIM

Find a price of Medium / Medium Additives ・ F-Media bulk with JDMF offered by BOEHRINGER INGELHEIM

Find a price of Medium / Medium Additives-P-Media bulk with JDMF offered by BOEHRINGER INGELHEIM

Find a price of Beperuminogen per plasmid bulk with JDMF offered by BOEHRINGER INGELHEIM

Find a price of Medium / Medium Additives / G-Medium bulk with JDMF offered by BOEHRINGER INGELHEIM

Find a price of Medium / Medium Additives-I-Medium bulk with JDMF offered by BOEHRINGER INGELHEIM

Find a price of Amphetamine bulk offered by BOEHRINGER INGELHEIM

Find a price of Beta-2 bulk offered by BOEHRINGER INGELHEIM

Find a price of Brompheniramine Maleate bulk offered by BOEHRINGER INGELHEIM

Find a price of Caffeine bulk offered by BOEHRINGER INGELHEIM

Find a price of Calcium Polycarbophil bulk offered by BOEHRINGER INGELHEIM

Find a price of Camptothecine bulk offered by BOEHRINGER INGELHEIM

Find a price of Crotamiton bulk offered by BOEHRINGER INGELHEIM

Find a price of Dexrazoxane bulk offered by BOEHRINGER INGELHEIM

Find a price of Digoxin bulk offered by BOEHRINGER INGELHEIM

Find a price of Dihydroergotoxine Mesylate bulk offered by BOEHRINGER INGELHEIM

Find a price of Esmolol Hydrochloride bulk offered by BOEHRINGER INGELHEIM

Find a price of Fentanyl bulk offered by BOEHRINGER INGELHEIM

Find a price of Fentanyl Citrate bulk offered by BOEHRINGER INGELHEIM

Find a price of Glycopyrronium Bromide bulk offered by BOEHRINGER INGELHEIM

Find a price of Guaifenesin bulk offered by BOEHRINGER INGELHEIM

Find a price of Isoproterenol Hydrochloride bulk offered by BOEHRINGER INGELHEIM

Find a price of L-Lactide bulk offered by BOEHRINGER INGELHEIM

Find a price of Lanthanum Carbonate bulk offered by BOEHRINGER INGELHEIM

Find a price of Lobeline Sulfate bulk offered by BOEHRINGER INGELHEIM

Find a price of Meloxicam bulk offered by BOEHRINGER INGELHEIM

Find a price of Metaproterenol Hemisulfate bulk offered by BOEHRINGER INGELHEIM

Find a price of Metaxalone bulk offered by BOEHRINGER INGELHEIM

Find a price of Methadol Hydrochloride bulk offered by BOEHRINGER INGELHEIM

Find a price of Methadone Hydrochloride bulk offered by BOEHRINGER INGELHEIM

Find a price of Methscopolamine Bromide bulk offered by BOEHRINGER INGELHEIM

Find a price of Methscopolamine Nitrate bulk offered by BOEHRINGER INGELHEIM

Find a price of Metoclopramide bulk offered by BOEHRINGER INGELHEIM

Find a price of Milrinone bulk offered by BOEHRINGER INGELHEIM

Find a price of Physostigmine Salicylate bulk offered by BOEHRINGER INGELHEIM

Find a price of Pilocarpine Hydrochloride bulk offered by BOEHRINGER INGELHEIM

Find a price of Ranitidine Hydrochloride bulk offered by BOEHRINGER INGELHEIM

Find a price of Scopolamine Hydrobromide bulk offered by BOEHRINGER INGELHEIM

Find a price of Theophylline bulk offered by BOEHRINGER INGELHEIM

Find a price of Tiotropium Bromide bulk offered by BOEHRINGER INGELHEIM

Find a price of Yohimbine Hydrochloride bulk offered by BOEHRINGER INGELHEIM

Find a price of PRODUCTION AND DISTRIBUTION FACILITY IN DANBURY, CONNECTICUT bulk offered by BOEHRINGER INGELHEIM

Find a price of NR-LU-10 MURINE MONOCLONAL ANTIBODY FAB FRAGMENT (NOFETUMOMAB) AND PHENTHIOATE LIGAND BULK MATERIAL FOR ONCOTRAC KIT (NEORX) bulk offered by BOEHRINGER INGELHEIM

Find a price of COPOLYMERS OF TRIMETHYLENE CARBONATE WITHL- OR D,L-LACTIDE bulk offered by BOEHRINGER INGELHEIM

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN RIDGEFIELD, CONNECTICUT. bulk offered by BOEHRINGER INGELHEIM

Find a price of rTNF-alpha Drug Substance bulk offered by BOEHRINGER INGELHEIM

Find a price of IFN-OMEGA bulk offered by BOEHRINGER INGELHEIM

Find a price of POLY-(D,L-LACTIDE-CO-GLYCOLIDE) 50:50 bulk offered by BOEHRINGER INGELHEIM

Find a price of PHYSOSTIGMINE SALICYLATE (SYNTHETIC bulk offered by BOEHRINGER INGELHEIM

Find a price of INTERLEUKIN-12 BULK SUBSTANCE bulk offered by BOEHRINGER INGELHEIM

Find a price of ESERETHOL bulk offered by BOEHRINGER INGELHEIM

Find a price of Bromhexine Hydrochloride bulk offered by BOEHRINGER INGELHEIM

Find a price of Penethamate Hydriodide bulk offered by BOEHRINGER INGELHEIM

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty